A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
about
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
P2860
A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A cellular replicon-based phen ...... to NS3/4A protease inhibitors.
@en
A cellular replicon-based phen ...... to NS3/4A protease inhibitors.
@nl
type
label
A cellular replicon-based phen ...... to NS3/4A protease inhibitors.
@en
A cellular replicon-based phen ...... to NS3/4A protease inhibitors.
@nl
prefLabel
A cellular replicon-based phen ...... to NS3/4A protease inhibitors.
@en
A cellular replicon-based phen ...... to NS3/4A protease inhibitors.
@nl
P2093
P1476
A cellular replicon-based phen ...... to NS3/4A protease inhibitors
@en
P2093
Barbara Van Kerckhove
Diana Koletzki
Gregory Fanning
Jan Martin Berke
Leen Vijgen
Oliver Lenz
P304
P356
10.1007/978-1-62703-484-5_9
P407
P577
2013-01-01T00:00:00Z